Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review

Ticagrelor is a potent P2Y12 receptor antagonist that may have a role in acute ischemic stroke (AIS), particularly in patients with symptomatic atherosclerotic disease.1,2 Recently, a large randomized control trial demonstrated a significant reduction in stroke or death within 30 days following minor stroke or TIA with ticagrelor plus aspirin versus aspirin alone.3 Studies of ticagrelor have focused on patients with minor stroke or TIA; however, safety of ticagrelor following more severe ischemic strokes is unknown.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research